Oct. 13, 2009--The European Medicines Agency has been formally notified by GlaxoSmithKline Research and Development Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zunrisa (casopitant mesilate), 50 mg and 150 mg film coated tablets.
The details can be read here.
No comments:
Post a Comment